Available online at www.sciencedirect.com

SciVerse ScienceDirect

journal homepage: www.elsevier.com/locate/mjafi

Short Communication

Intravenous immunoglobulin in pediatrics: A review

Lt Col A.N. Prasad*, Surg Cdr Sanjay Chaudhary

Classified Specialist (Pediatrics), Command Hospital (Western Command), Chandimandir, Panchkula 134107, Haryana, India

ARTICLE INFO

Article history:

Received 21 September 2012

Accepted 28 May 2013

Available online 6 August 2013

Keywords:

Immunoglobulin

Agammaglobulinemia

Autoimmune disorder

ABSTRACT

There has been a rapid expansion of the use of intravenous immunoglobulin (IVIG) for an ever-growing number of conditions. IVIG is used at a 'replacement dose' (400–600 mg/kg/month) in antibody deficiencies and is used at a high dose (2 g/kg) as an 'immunomodulatory' agent in an increasing number of immune and inflammatory disorders.¹ The limitations for IVIG are the cost of the preparation and the need for intravenous infusions. Due to the cost, shortages and growing use of IVIG there have been attempts to develop evidence-based guidelines for the use of IVIG in a wide variety of immune disorders in children and neonates. This commentary provides the recommendations and recent publication regarding the use of IVIG in various conditions in children.

© 2013, Armed Forces Medical Services (AFMS). All rights reserved.

Introduction

There has been a rapid expansion of the use of intravenous immunoglobulin (IVIG) for an ever-growing number of conditions in children and neonates.¹ IVIG has a few proven indications and many potential ones. It has had a major impact in the treatment of conditions in the fields of neurology, haematology, rheumatology and dermatology. It is safe and does not have the side-effects of steroids or other immunosuppressive agents. IVIG is used at a 'replacement dose' (400–600 mg/kg/month) in antibody deficiencies and is used at a high dose (2 g/kg) as an 'immunomodulatory' agent in an increasing number of immune and inflammatory disorders.² The limitations for IVIG are the cost of the preparation and the need for intravenous infusions. Due to the cost, shortages and growing use of IVIG there is a growing need to develop evidence-based guidelines for the use of IVIG in a wide variety

of immune disorders in children and neonates. Here, we present a review of IVIG use in children, along with some of the common uses at our centre.

IVIG: its advent and importance

Immunoglobulin replacement has been standard therapy for patients with primary immune deficiency diseases since its use by Bruton in 1952.^{3,4} For many years, these preparations could only be given intramuscularly. However injections were painful, the IgG was absorbed slowly and it was difficult to maintain IgG levels above 2 g/l. Although attempts were made to modify immune serum globulin for intravenous use, intramuscular use remained the sole form of replacement therapy until 1981 (29 years later) when intravenous preparations became commercially available. This reduced the pain

* Corresponding author. Tel.: +91 9872626949.

E-mail address: dranprasad@gmail.com (A.N. Prasad).

0377-1237/\$ – see front matter © 2013, Armed Forces Medical Services (AFMS). All rights reserved.

<http://dx.doi.org/10.1016/j.mjafi.2013.05.011>

of administration and allowed larger volumes to be infused. Today, over 25 IVIG preparations are available worldwide which have been approved by various regulatory bodies.⁵ The various IVIG products differ in a number of ways including immunoglobulin and IgG subclass distribution, antibody content, approved maximum infusion rate and side-effects.⁶ The characteristics of the various products may result in differences in efficacy and safety which may have a significant impact on the choice of product for some patients. Differences in the manufacturing processes of different IVIG preparations affect opsonic activity, Fc-receptor function and complement fixation.^{5,6} An ideal IVIG preparation would contain structurally and functionally intact immunoglobulin molecules with a normal biological half-life and a normal proportion of IgG subclasses. The preparation should contain high levels of antibody or antibodies relevant to its proposed use. All IVIG preparations are isolated from pooled human plasma (1000–10,000 donors) by the Cohn alcohol fractionation method which results in five plasma fractions.⁶ The Cohn fraction II contains the bulk of the antibodies for therapeutic use. This fraction is further purified for the production of IVIG. The WHO has established the following production criteria for IVIG (1982)⁷:

1. Each lot should be derived from plasma pooled from at least 1000 donors.
2. It should contain at least 90% intact IgG with the subclasses present in ratios similar to normal pooled plasma.
3. IgG molecules should maintain biological activity such as complement fixation.
4. It should be free from contaminants of prekallikrein activator kinins, plasma proteases and preservatives.
5. It should be free from infectious agents. As for all blood products donors are screened for hepatitis B surface antigen, HIV-p24 antigen, and antibodies to syphilis, HIV-1, HIV-2 and hepatitis C.

IVIG acts via a variety of mechanisms in different disease states. The mechanisms of action of therapeutic IVIG are complex. In many conditions advances in the understanding of its actions have been made. The predominant mechanisms depend on both the IVIG dose and on the pathogenesis of the underlying disease and can be divided into four broad groups⁸:

1. Actions mediated via the variable regions Fab.
2. Actions of Fc region on a range of receptors.
3. Actions mediated by complement binding within the Fc fragment.
4. Immunomodulatory substances other than antibody in the IVIG preparations.

When to use

IVIG's effect last between 2 weeks and 3 months. It is mainly used as treatment in three major categories⁹: (a) Immune deficiencies such as X-linked agammaglobulinemia, hypogammaglobulinemia (primary immune deficiencies), and acquired compromised immunity conditions (secondary immune deficiencies) featuring low antibody levels. (b) Autoimmune

diseases, e.g. Immune thrombocytopenia (ITP), and Inflammatory diseases, e.g. Kawasaki disease. (c) Acute infections.

IVIG is an infusion of IgG antibodies only. Therefore, peripheral tissues that are defended mainly by IgA antibodies, such as the eyes, lungs, gut and urinary tract are not fully protected by IVIG treatment. IVIG has many uses and is an important treatment in many diseases. The original use was as replacement therapy (400–600 mg/kg/month) in primary and secondary antibody deficiencies. However, IVIG has many immunomodulatory and anti-inflammatory effects at higher doses (2 g/kg/d) and now more than 100 inflammatory and autoimmune disorders are treated with IVIG.^{9,10} IVIG therapy has a few proven indications and many potential ones. There are currently six clinical indications in the USA with Food and Drug Administration (FDA) approval⁹:

1. Treatment of primary immunodeficiencies.
2. Prevention of bacterial infections in patients with hypogammaglobulinaemia and recurrent infection caused by B-cell chronic lymphocytic leukaemia.
3. Prevention of coronary artery aneurysms in Kawasaki disease.
4. Prevention of infections, pneumonia and acute graft versus host disease (GVHD) after bone marrow transplantation.
5. Reduction of serious bacterial infection in children with HIV.
6. Increase of platelet count in idiopathic thrombocytopenic purpura to prevent or control bleeding.

There are many disorders for which IVIG is used as a treatment in children. Some of the common indications can be grouped as^{9–14}:

- a) Neurology – Guillain Barre syndrome, Chronic inflammatory demyelinating polyradiculopathy (CIDP), Dermatomyositis and inflammatory myopathies, Myasthenia gravis, rare childhood epilepsy (Lennox gastaut seizure, Landau kleffner seizure), Opsoclonus myoclonus ataxia, PANDAS (Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection) – OCD, anxiety, depression, emotional lability.
- b) Haematology – Idiopathic thrombocytopenic purpura, Pure red cell aplasia, Pure white cell aplasia, Immune neutropenia, Immune haemolytic anaemia.
- c) Immunology – Primary antibody deficiencies (XLA, CVID, HIGM, WAS and others), Secondary antibody deficiencies.
- d) Dermatology – Kawasaki syndrome, Dermatomyositis, Toxic epidermal necrolysis, Blistering diseases, Immune urticaria, Atopic dermatitis, Pyoderma gangrenosum.
- e) Neonatology – Haemolytic disease of newborn due to Rh and ABO incompatibility, Neonatal alloimmune thrombocytopenic purpura, Bacterial sepsis in preterms.
- f) Others – Myocarditis, Systemic lupus erythematosus, Streptococcal toxic shock syndrome, Autoimmune uveitis.

IVIG dose

The usual dose of IVIG for antibody replacement is between 400 and 600 mg/kg of body weight every 2–4 weeks. The dose

is adjusted so that the trough level just before the next infusion is at least 500 mg/dl. For other uses the doses range between 400 mg/kg/day for 5 days or a more rapid course of 1–2 g/kg given over 1–2 days.

In agammaglobulinaemic patients the dose of IVIG is needed to keep the patient symptom-free, and depends on the severity of the antibody defect and the catabolic rate of infused IVIG. The therapeutic dose is the one that prevents serious infections and prevents the patient from getting more infections than the general population. Dosage of 400 mg/kg or greater have improved efficacy in reducing the incidence of infection. After the sixth infusion a steady state will have been achieved and the dose or dosing interval should be altered to achieve the optimal clinical result. A dose must be individualised and titrated to achieve best clinical effect for each patient. Dose adjustments will be needed with children's growth or in protein-losing conditions. If patients who are receiving IVIG every 28 days experience malaise or upper respiratory tract symptoms in the week before infusion, a more frequent dosing schedule should be considered. In contrast to the 'replacement' dose of 400 mg/kg/month, the 'high' dose IVIG is given at 2 g/kg (over 2–5 days for adults, 2 days for children) when it is used as an immunomodulatory agent in immune or inflammatory disorders. For neurological and autoimmune diseases 2 g/kg of body weight is implemented for 3–6 months over a 5-day course once a month. Then maintenance therapy of 100–400 mg/kg of body weight every 3–4 weeks follows.

Adverse effects

Systemic reactions to IVIG infusion range from 3% to 15%.¹⁵ They are usually self-limiting and can be avoided by decreasing the rate of the infusion. Infusion rates are usually started at 0.01–0.02 ml/kg/min and increased up to 0.1 ml/kg/min. Most IVIG reactions are mild and nonanaphylactoid. Typically they include backache, abdominal pain, nausea, chills, rhinitis, low-grade fever, myalgia and headaches. More serious adverse events can occur during or soon after infusion: anaphylaxis, renal, cardiovascular, central nervous system and haematological events have been reported.¹⁶

Anaphylaxis is very rare and is associated with anti-IgA antibodies in some patients with total IgA deficiency (IgA < 0.05 g/l). Acute renal failure and neurodegeneration have been associated with IVIG but not temporally related to the infusion. It has been suggested that the sucrose-based products are more commonly associated with acute renal failure. Risk of hepatitis B, hepatitis C and HIV transmission through IVIG can also occur rarely.

Conclusion

Because of the cost, shortages and growing use of IVIG there have been attempts in many countries to develop guidelines for monitoring of and indications for the use of IVIG.^{15,17} Clinicians should limit their prescription of IVIG to conditions for which efficacy is supported by evidence-based studies. In India also, it must be ensured that the patients who will benefit most from IVIG (determined from evidence-based

guidelines) will have access to this treatment. Some of the definite indications of IVIG in neonates and children, where IVIG should be used in our country, is as follows:-

- a) Primary immunodeficiency states: XLA, CVID, HIGM, WAS and others.
- b) Kawasaki disease.
- c) Idiopathic thrombocytopenic purpura.
- d) Guillain Barre syndrome, Chronic inflammatory demyelinating polyradiculopathy (CIDP).
- e) Reduction of serious bacterial infection in children with HIV.
- f) Neonatology: Haemolytic disease of newborn due to Rh and ABO incompatibility, Neonatal alloimmune thrombocytopenic purpura, Bacterial sepsis in preterms.

Although there is statutory documentation for the use of blood in our country, there are no guidelines for the use or monitoring of IVIG.

Conflicts of interest

All authors have none to declare.

REFERENCES

1. Stiehm ER, Keller MA, Vyas GN. Preparation and use of therapeutic antibodies primarily of human origin. *Biologicals*. 2008;6:363–374.
2. Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. *Clin Exp Immunol*. 2005;142:1–11.
3. Bruton OC. Agammaglobulinaemia. *Pediatrics*. 1952;9:722–728.
4. Schroeder Jr HW, Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. *Infection*. 2012;40(6):601–611.
5. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. *Immunol Allergy Clin North Am*. 2008;28(4):765–778.
6. Luzi G, Bongiorno F, Paparo Barbaro S, Bruno G. Intravenous IgG: biological modulating molecules. *J Biol Regul Homeost Agents*. 2009;23(1):1–9.
7. Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting. *WHO Bull*. 1982;60:43–47.
8. Hartung HP. Advances in the understanding of the mechanism of action of IVIg. *J Neurol*. 2008;255(suppl 3):3–6.
9. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology. *J Allergy Clin Immunol*. 2006;117:S525–S553.
10. Leong H, Stachnik J, Bonk ME. Unlabeled uses of intravenous immune globulin. *Am J Health Syst Pharm*. 2008;65(19):1815–1824.
11. Robinson P, Andersen D, Brouwers M, et al. Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. *Transfus Med Rev*. 2007;21:S3–S8.
12. Hughes R. Advances in the use of IVIg in neurological disorders. *J Neurol*. 2008;255(suppl 3):1–2.

13. Gottstein R, Cooke RW. Systemic review of intravenous immunoglobulin in haemolytic disease of the newborn. *Arch Dis Child Fetal Neonatal Ed.* 2003;88:F6–F10.
14. Ishii N, Hashimoto T, Zillikens D, Ludwig RJ. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. *Clin Rev Allergy Immunol.* 2010;38(2–3):186–195.
15. Goddard EA. Intravenous immunoglobulin. *Curr Allergy Clin Immunol.* 2008;21:26–31.
16. Graumann Aaron, Zawada Edward T. Case report: acute renal failure after administering intravenous immunoglobulin. *Postgrad Med.* 2010;122(2):142–147.
17. Constantine MM, Thomas W, Whitman L, et al. Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group. *Transfusion.* 2007;47:2072–2080.